Erectile Dysfunction Following Radical ProstatectomyNCT04164355
Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg
An observational study of Erectile Dysfunction Following Radical Prostatectomy, run by Federico II University at 1 site in Italy.
Trial summary
This study evaluates the retinal and choriocapillary vascular features in patients under the effects of Tadalafil 20mg using optical coherence tomography angiography. Read more about this study
- Who is it for?
- Ages 45 to 80 years, men only
- Conditions the study is for
- Erectile Dysfunction Following Radical Prostatectomy
- What is being tested?
- Tadalafil 20 MG
- Type of treatment
- Pill or oral medicine
- How many people
- 40 participants
- Where
- 1 siteItaly
- Study dates
- 4 Jul 2020to 30 Apr 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 80 years
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: The participans were older than 45 years with diagnosis of erectile dysfunction due to surgery of radical prostatectomy. They did not receive previous treatment before Tadalafil and they have not other ophthalmological disease and diabetes.
Who may be able to join
- age older than 45 years
- diagnosis of erectile dysfunction due to surgery of radical prostatectomy
- treatment-naïve with Tadalafil for erectile dysfunction
- absence of vitreoretinal and vascular retinal diseases
- absence of diabetes
Who cannot join
- age younger than 45 years
- diagnosis of erectile dysfunction due to other causes
- previous treatments before Tadalafil for erectile dysfunction
- presence of vitreoretinal and vascular retinal diseases
- presence of diabetes.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Retinal and Choriocapillary Vascular Changes Using Optical Coherence Tomography Angiography in Patients Undergoing Tadalafil 20mg on Alternative Days: a Single-centre Prospective-control
This study evaluates the retinal and choriocapillary vascular features in patients under the effects of Tadalafil 20mg using optical coherence tomography angiography.
Read the detailed description
Tadalafil is a an inhibitor of the enzyme phosphodiesterase and it works by increasing blood flow to the penis thus promoting the erection.
This drug represents an treatment for erectile dysfunction in patients after radical prostatectomy.
The optical coherence tomography angiography represents a novel and non-invasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features.
The study evaluates the changes in optical coherence tomography angiography parameters at baseline and after 1, 3, 6 months after the somministration of Tadalafil 20 mg orally.
- Being tested
- Tadalafil 20 MG
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tadalafil 20 MGDrug
Also called Cialis
To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
| Study group | Role | What they receive |
|---|---|---|
| Patients undergoing Tadalafil | Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for 6 months Receives: Drug: Tadalafil 20 MG | |
| Control Group | Healthy controls without previous surgery of radical prostatectomy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The measurements of retinal and choriocapillary vessel density in patients undergoing Tadalafil after radical prostatectomy
Changes in retinal and choriocapilary vessel density in 40 patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy, using optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillary vessel density
Measured: Six months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2019
- Study start4 Jul 2020
- Primary completion25 Apr 2021
- Study completion30 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Erectile Dysfunction Following Radical ProstatectomyStudies of the same condition, open and under way.
- More trials run by Federico II UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Federico II University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gilda Cennamo, Federico II University
- Investigators
- Gilda Cennamo, Principal investigator, Federico II University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04164355
- Sponsor's protocol ID
- PT1515/19
- Status last verified
- Sep 2021
- First submitted
- 11 Nov 2019
- Last updated
- 24 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Retinal and Choriocapillary Vascular Changes Using Optical Coherence Tomography Angiography in Patients Undergoing Tadalafil 20mg on Alternative Days: a Single-centre Prospective-control
- ClinicalTrials.gov ID
- NCT04164355
- Acronym / sponsor ID
- PT1515/19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Federico II UniversityUniversity, hospital or other
- Study start
- 4 Jul 2020 (actual)
- Primary completion
- 25 Apr 2021 (actual)
- Study completion
- 30 Apr 2021 (actual)
- First posted
- 15 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the retinal and choriocapillary vascular features in patients under the effects of Tadalafil 20mg using optical coherence tomography angiography.
Detailed description
Tadalafil is a an inhibitor of the enzyme phosphodiesterase and it works by increasing blood flow to the penis thus promoting the erection.
This drug represents an treatment for erectile dysfunction in patients after radical prostatectomy.
The optical coherence tomography angiography represents a novel and non-invasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features.
The study evaluates the changes in optical coherence tomography angiography parameters at baseline and after 1, 3, 6 months after the somministration of Tadalafil 20 mg orally.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients undergoing Tadalafil | – | Drug: Tadalafil 20 MGPatients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for 6 months |
| Control Group | – | –Healthy controls without previous surgery of radical prostatectomy. |
Who may qualify
- Ages
- 45 to 80 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The participans were older than 45 years with diagnosis of erectile dysfunction due to surgery of radical prostatectomy. They did not receive previous treatment before Tadalafil and they have not other ophthalmological disease and diabetes.
Key inclusion criteria (5 listed)
- age older than 45 years
- diagnosis of erectile dysfunction due to surgery of radical prostatectomy
- treatment-naïve with Tadalafil for erectile dysfunction
- absence of vitreoretinal and vascular retinal diseases
- absence of diabetes
Key exclusion criteria (5 listed)
- age younger than 45 years
- diagnosis of erectile dysfunction due to other causes
- previous treatments before Tadalafil for erectile dysfunction
- presence of vitreoretinal and vascular retinal diseases
- presence of diabetes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tadalafil 20 MGAlso: CialisTo study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy | Drug | Patients undergoing Tadalafil |
Primary outcome
The measurements of retinal and choriocapillary vessel density in patients undergoing Tadalafil after radical prostatectomy
Time frame: Six months
Changes in retinal and choriocapilary vessel density in 40 patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy, using optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillary vessel density
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2021.
Related trials for Erectile Dysfunction Following Radical Prostatectomy
Recruiting
Platelet-Rich Plasma for Erectile Dysfunction After Radical Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction
RecruitingPhase 2
Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer
Not yet recruiting
Shockwave Therapy on Treating Erectile Dysfunction Following Nerve-sparing Radical Prostatectomy.
Erectile Dysfunction
Recruiting
Tractography-Guided Nerve-Sparing in Prostate Cancer
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy
Active, not recruiting
Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction
Erectile Dysfunction Following Radical Prostatectomy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gilda Cennamo principal investigator
Federico II University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Erectile Dysfunction Following Radical Prostatectomy, run by Federico II University at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The measurements of retinal and choriocapillary vessel density in patients undergoing Tadalafil after radical prostatectomy (time frame: Six months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2021.